(Total Views: 613)
Posted On: 11/12/2022 10:26:00 AM
Post# of 148870
I remember some comments, from Dr Recknor, concerning bio markers that they are studying to, possibly, use as endpoints for various trials. He stated that gut microbiota was one of these bio markers. My takeaway, from that, was that Leronlimab was showing positive effect on this microbiome.
Here is an article, from Nature Communications, showing some of the relationship of the gut microbiome with COVID-19, cancer, and treatment with broad spectrum antibiotics (when no actual bacterial infection was present). A couple of paragraphs from the article:
Differences in gut bacterial populations relative to healthy controls were observed in all COVID-19 patients, but most strongly in patients who were treated with antibiotics during their hospitalization4. Most recently, COVID-19 patients treated with broad-spectrum antibiotics at admission were shown to have increased susceptibility to multi-drug resistant infections and nearly double the mortality rate from septic shock9,10.
In immunocompromised cancer patients, blooms of Enterococcaceae and Gram-negative proteobacteria can lead to gut dominations by few or single species22,23,24,25. Such gut domination events are dangerous to these patients because they are associated with increased risk of translocation of antibiotic-resistant bacteria from the gut into the blood stream22,26,27. Bacterial co-infection can also cause life-threatening complications in patients with severe viral infections10,11,28; therefore, antibacterial agents were administered empirically to nearly all critically ill suspected COVID-19 patients since the incidence of bacterial superinfection was unknown early during the pandemic4,29.
https://www.nature.com/articles/s41467-022-33395-6
Here is an article, from Nature Communications, showing some of the relationship of the gut microbiome with COVID-19, cancer, and treatment with broad spectrum antibiotics (when no actual bacterial infection was present). A couple of paragraphs from the article:
Differences in gut bacterial populations relative to healthy controls were observed in all COVID-19 patients, but most strongly in patients who were treated with antibiotics during their hospitalization4. Most recently, COVID-19 patients treated with broad-spectrum antibiotics at admission were shown to have increased susceptibility to multi-drug resistant infections and nearly double the mortality rate from septic shock9,10.
In immunocompromised cancer patients, blooms of Enterococcaceae and Gram-negative proteobacteria can lead to gut dominations by few or single species22,23,24,25. Such gut domination events are dangerous to these patients because they are associated with increased risk of translocation of antibiotic-resistant bacteria from the gut into the blood stream22,26,27. Bacterial co-infection can also cause life-threatening complications in patients with severe viral infections10,11,28; therefore, antibacterial agents were administered empirically to nearly all critically ill suspected COVID-19 patients since the incidence of bacterial superinfection was unknown early during the pandemic4,29.
https://www.nature.com/articles/s41467-022-33395-6
(4)
(0)Scroll down for more posts ▼
